ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data – FierceBiotech
FierceBiotech |
ASCO dark horse Nanjing Legend Biotech shines with promising CAR–T data
FierceBiotech Chinese firm Nanjing Legend Biotech grabbed attention at the American Society of Clinical Oncology (ASCO) annual meeting, showing that its CAR–T candidate could be a safe and effective way to treat relapsed or refractory multiple myeloma. Researchers … bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter … Bluebird, Celgene CAR–T Keeps Multiple Myeloma Patients Relapse Free |
